The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-025-09282-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Eva Futtrup Maksten und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Section, Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, 9000, Aalborg, Denmark. ef…. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Antineoplastic Combined Chemotherapy Protocols, Hematologic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Master Carpenter Jørgen Holm and wife Elisa born Hansen's memorial trust, Dagmar Marshalls Foundation, The Danish National Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To assess and describe chemotherapy-induced peripheral neuropathy (CIPN), a well-known complication to cancer treatment, using different methodologies in hematological patients.
Methods
Patients scheduled for treatment with vincristine, bortezomib, or lenalidomide were included in this longitudinal observational study. The patients were examined for CIPN before treatment (baseline), before each chemotherapy cycle, one month after end of treatment, and one year after baseline using patient-reported outcomes (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Ntx-13 (FACT/GOG-Ntx-13)) and clinician-assessed outcomes (the Common Terminology Criteria for Adverse Events (CTCAE) and the Total Neuropathy Score-clinical version (TNSc©)).
Results
A total of 23 patients with 171 examination visits were included between 2020 and 2022. Four patients were treated with vincristine, five with bortezomib, and fourteen with bortezomib and lenalidomide combined. Defining CIPN as a ≥ 10% decrease in the FACT/GOG-Ntx-13, 11 patients (47.8%) developed CIPN during treatment and follow-up. CTCAE score for paresthesia increased from baseline throughout treatment until 1 month after the last treatment (p ≤ 0.045). Overall, the highest proportion of CIPN was present at cycle 3–4 and 1 month after last treatment.
Conclusion
This study describes the course of CIPN in patients treated with vincristine, bortezomib, or lenalidomide using both patient-reported and clinician-assessed outcomes. The highest proportion of CIPN was present at cycle 3–4 and 1 month after treatment, at which timepoints clinicians must be especially aware of CIPN.
Trial registration
Registered at Clinicaltrials.gov (Trial Registration Number: NCT04393363) on March 19, 2020.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Section, Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, 9000, Aalborg, Denmark. efm@rn.dk.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. efm@rn.dk.
- Center for Neuroplasticity and Pain (CNAP), Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
- Research Section, Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, 9000, Aalborg, Denmark.
- Department Mathematical Sciences, Aalborg University, Aalborg, Denmark.
- Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Förderung
- Master Carpenter Jørgen Holm and wife Elisa born Hansen's memorial trust
- Dagmar Marshalls Foundation
- The Danish National Research Foundation
- Master Carpenter Jørgen Holm and wife Elisa born Hansen’s memorial trust
- Medical specialist Heinrich Kopp’s Foundation
- The Karen Elise Jensen Foundation
- The Nordic Cancer Union
- Aalborg University Hospital
Zitieren
APA
Maksten, E. F., Mørch, C. D., Jakobsen, L. H., Kragholm, K. H., Blindum, P. F., Simonsen, M. R., Ejskjaer, N., Dybkær, K., Gregersen, H., Madsen, J., El-Galaly, T. C., & Severinsen, M. T. (2025). The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09282-3
Vancouver
Maksten EF, Mørch CD, Jakobsen LH, Kragholm KH, Blindum PF, Simonsen MR, et al. The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09282-3
BibTeX
@article{Maksten2025,
author = {Maksten, Eva Futtrup and Mørch, Carsten Dahl and Jakobsen, Lasse Hjort and Kragholm, Kristian Hay and Blindum, Pernille From and Simonsen, Mikkel Runason and Ejskjaer, Niels and Dybkær, Karen and Gregersen, Henrik and Madsen, Jakob and El-Galaly, Tarec C and Severinsen, Marianne Tang},
title = {The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-025-09282-3}
}
EUVIMED